Bio-Connect
GTX28414 WB Image
GTX28414 WB Image
GTX28414 WB Image

DR4 antibody - KO/KD Validated

Research Use Only
GTX28414
GeneTex
ApplicationsImmunoFluorescence, Western Blot, ELISA, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse, Rat
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    DR4 antibody - KO/KD Validated
  • Delivery Days Customer
    10
  • Applications
    ImmunoFluorescence, Western Blot, ELISA, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    1 mg/ml
  • Host
    Rabbit
  • Isotype
    IgG
  • Scientific Description
    Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1and Fas. A novel cell death receptor was recently identified and designated DR4 (for death receptor4)(1). The ligand for this novel death receptor has been identified and termed TRAIL (2,3), which is a new member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1)(4). DR4 is expressed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4mediates apoptosis and NF-kB activation in many tissues and cells.
  • Reactivity
    Human, Mouse, Rat
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352203

References

  • Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis. Ou YC et al., 2014 Apr 1, Life Sci
    Read more
  • MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Greer YE et al., 2019 Feb 18, Breast Cancer Res
    Read more
  • The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Dine JL et al., 2016 Jan, Breast Cancer Res Treat
    Read more
  • WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Garimella SV et al., 2012 Jan, Mol Cancer Res
    Read more